The Role of Physician Networks in the Adoption of New Prescription Drugs.
医生网络在采用新处方药中的作用。
基本信息
- 批准号:8719165
- 负责人:
- 金额:$ 75.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-15 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:Academic DetailingAdoptedAdoptionAdultAffectBehaviorBenefits and RisksBudgetsCardiovascular DiseasesCaringCase MixesCharacteristicsChronicDataData AnalysesData SetDevelopmentDiabetes MellitusDiffusionDrug PrescriptionsDrug usageEnrollmentEvidence Based MedicineEvidence based treatmentExhibitsFaceHealth StatusHealth systemHealthcareHeart failureHospital ReferralsHospitalsHyperlipidemiaInstitutionInterventionLearningLinkLocationMeasurementMeasuresMedicalMedicareMedicare/MedicaidMedicineMorbidity - disease rateMyocardial IschemiaNamesPathway AnalysisPatient CarePatientsPennsylvaniaPharmaceutical PreparationsPharmacotherapyPhysician&aposs RolePhysiciansPlayPositioning AttributeProcessResidenciesRestRoleServicesSocioeconomic StatusSourceSpeedStrokeTechniquesTechnologyTherapeuticTimeTrainingVariantbeneficiarycostevidence baseimprovedmedical specialtiesmortalitynon-drugpeerpeer influencepressurepreventprogramspublic health relevancetooluptake
项目摘要
DESCRIPTION (provided by applicant): Medications to treat and prevent cardiovascular disease (CVD) have substantially reduced CVD-related morbidity and mortality; however, their diffusion has been uneven. Physicians have been slow to adopt some evidence-based treatments and have rapidly adopted others of low value. Use of newer, brand name drugs is much higher in some regions in the US and suggests that physicians in those regions are rapid adopters of new drugs. Yet the determinants of physician adoption of new medications are poorly understood. Physicians are likely to turn to their peers for information on drugs' uses, benefits and risks. Network analysis offers an analytic framework and measurement techniques for understanding how physicians learn from each other about new treatments. Our long-term objective is to understand the role of physician networks in technology diffusion. To accomplish this objective, we propose two specific aims. First, we will examine the association at the local-level between physician adoption of new medications and prescription drug spending and total non-drug medical spending. We will measure the rate and speed of adoption among nearly all physicians in Pennsylvania of 5 new drugs used for CVD or diabetes introduced in recent years. We will obtain data on prescribing for nearly all of Pennsylvania's 50,000 physicians. We will also obtain Medicare and Medicaid claims data for the more than 2 million adults in the state who are covered by these programs. Second, we will examine the influence of multiple types of professional networks, physician characteristics, patient characteristics, and institutions on physician adoption of new medications. In particular, we will assess the influence on physician adoption of new drugs of physician networks formed during training (e.g., residency program), in organizations (e.g., medical groups, hospitals), and through the sharing (referral) of patients. Understanding the role of these networks will guide dissemination of interventions such as academic detailing to improve the quality and efficiency of pharmacotherapy. Medicare and Medicaid are key settings for studying network effects because they provide coverage to the most vulnerable and because the costs of these programs exert substantial pressure on public budgets.
描述(由申请人提供):治疗和预防心血管疾病(CVD)的药物大大降低了与CVD相关的发病率和死亡率;但是,它们的扩散是不平衡的。医生采用一些基于证据的治疗方法的速度很慢,并迅速采用了其他具有低价值的方法。在美国的某些地区,使用更新的品牌药物要高得多,并表明这些地区的医生是新药的快速采用者。然而,医师采用新药物的决定因素知之甚少。医生可能会向同龄人寻求有关药物用途,福利和风险的信息。网络分析提供了一种分析框架和测量技术,以了解医师如何相互学习新治疗。我们的长期目标是了解医师网络在技术扩散中的作用。为了实现这一目标,我们提出了两个具体目标。首先,我们将在医师采用新药物和处方药支出与全毒品医疗支出之间的本地级别检查协会。我们将衡量宾夕法尼亚州几乎所有医生的收养率和速度,用于近年来用于CVD或糖尿病的5种新药。我们将获得有关几乎所有宾夕法尼亚州50,000名医生开处方的数据。我们还将为该州涵盖的州超过200万成年人获得医疗保险和医疗补助索赔数据。其次,我们将研究多种类型的专业网络,医师特征,患者特征和机构对医师采用新药物的影响。特别是,我们将评估对医师在培训期间(例如居住计划),在组织(例如医疗团体,医院)以及患者共享(转诊)中对医师采用新药的影响。了解这些网络的作用将指导诸如学术细节之类的干预措施的传播,以提高药物治疗的质量和效率。 Medicare和Medicaid是研究网络效应的关键环境,因为它们为最脆弱的人提供了覆盖范围,并且因为这些计划的成本对公共预算施加了重大压力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JULIE Marie DONOHUE其他文献
JULIE Marie DONOHUE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JULIE Marie DONOHUE', 18)}}的其他基金
Improving racial equity in opioid use disorder treatment in Medicaid
改善医疗补助中阿片类药物使用障碍治疗的种族平等
- 批准号:
10415670 - 财政年份:2022
- 资助金额:
$ 75.57万 - 项目类别:
Improving racial equity in opioid use disorder treatment in Medicaid
改善医疗补助中阿片类药物使用障碍治疗的种族平等
- 批准号:
10683980 - 财政年份:2022
- 资助金额:
$ 75.57万 - 项目类别:
Examining the quality of opioid use disorder treatment in a Medicaid research network
检查医疗补助研究网络中阿片类药物使用障碍治疗的质量
- 批准号:
9896805 - 财政年份:2019
- 资助金额:
$ 75.57万 - 项目类别:
The Role of Physician Networks in the Adoption of New Prescription Drugs.
医生网络在采用新处方药中的作用。
- 批准号:
8557631 - 财政年份:2013
- 资助金额:
$ 75.57万 - 项目类别:
The Role of Physician Networks in the Adoption of New Prescription Drugs.
医生网络在采用新处方药中的作用。
- 批准号:
8851674 - 财政年份:2013
- 资助金额:
$ 75.57万 - 项目类别:
Influences on Psychiatrist Prescribing of Antipsychotics
对精神科医生开抗精神病药处方的影响
- 批准号:
8233719 - 财政年份:2012
- 资助金额:
$ 75.57万 - 项目类别:
Influences on Psychiatrist Prescribing of Antipsychotics
对精神科医生开抗精神病药处方的影响
- 批准号:
8451415 - 财政年份:2012
- 资助金额:
$ 75.57万 - 项目类别:
Influences on Psychiatrist Prescribing of Antipsychotics
对精神科医生开抗精神病药处方的影响
- 批准号:
8605927 - 财政年份:2012
- 资助金额:
$ 75.57万 - 项目类别:
Impact of Medicare Part D on Racial Disparities in Diabetes Treatment and Outcome
医疗保险 D 部分对糖尿病治疗和结果中种族差异的影响
- 批准号:
7938793 - 财政年份:2009
- 资助金额:
$ 75.57万 - 项目类别:
Impact of Medicare Part D on Racial Disparities in Diabetes Treatment and Outcome
医疗保险 D 部分对糖尿病治疗和结果中种族差异的影响
- 批准号:
7560147 - 财政年份:2009
- 资助金额:
$ 75.57万 - 项目类别:
相似国自然基金
采用新型视觉-电刺激配对范式长期、特异性改变成年期动物视觉系统功能可塑性
- 批准号:32371047
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
破解老年人数字鸿沟:老年人采用数字技术的决策过程、客观障碍和应对策略
- 批准号:72303205
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
通过抑制流体运动和采用双能谱方法来改进烧蚀速率测量的研究
- 批准号:12305261
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
采用多种稀疏自注意力机制的Transformer隧道衬砌裂缝检测方法研究
- 批准号:62301339
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
政策激励、信息传递与农户屋顶光伏技术采用提升机制研究
- 批准号:72304103
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Identifying Safe Stimulant Prescribing Practices to Protect Patients, Inform Key Program Initiatives, and Assist Providers
确定安全的兴奋剂处方实践以保护患者、为关键计划举措提供信息并协助提供者
- 批准号:
10534426 - 财政年份:2023
- 资助金额:
$ 75.57万 - 项目类别:
MIDAS: Maintaining Implementation through Dynamic Adaptations
MIDAS:通过动态调整维持实施
- 批准号:
10062256 - 财政年份:2020
- 资助金额:
$ 75.57万 - 项目类别:
Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment
传播和了解阿片类药物使用障碍治疗实施的联盟
- 批准号:
10181067 - 财政年份:2019
- 资助金额:
$ 75.57万 - 项目类别:
Implementation trial of a coaching intervention to increase the use of transradial PCI
实施指导干预试验以增加经桡动脉 PCI 的使用
- 批准号:
10186494 - 财政年份:2018
- 资助金额:
$ 75.57万 - 项目类别:
Implementation trial of a coaching intervention to increase the use of transradial PCI
实施指导干预试验以增加经桡动脉 PCI 的使用
- 批准号:
9655230 - 财政年份:2018
- 资助金额:
$ 75.57万 - 项目类别: